Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Merck Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer 2021-03-16 15:00
New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-treated RMS Patients Mount Protective Antibody Response to Common Vaccines 2021-02-25 21:00
European Medicines Agency Validates Application for Tepotinib for the Treatment of Advanced NSCLC with METex14 Skipping Alterations 2020-11-27 08:42
Merck Announces Out-Licensing Agreement for Investigational Atacicept with Vera Therapeutics 2020-11-09 21:00
Merck Announces Out-Licensing Agreement for Phase II-ready Anti-ADAMTS5 Nanobody for Osteoarthritis 2020-10-06 20:00
Merck Advances Oncology Portfolio and Pipeline with New and Long-term Data in Multiple Cancers at ESMO 2020 2020-09-14 10:41
New MAVENCLAD® Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting Highlight Rapid Onset of Action and Compelling Post-Approval Safety 2020-09-11 20:00
Merck Announces Positive Phase II Results for Investigational Sonelokinab (M1095) in Patients with Moderate to Severe Chronic Plaque-Type Psoriasis 2020-09-10 20:00
Merck to Showcase New Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting, Furthering Innovation in Multiple Sclerosis 2020-09-03 20:00
Merck and Twitch Join Forces on World Multiple Sclerosis Day to Connect People Living With MS 2020-05-28 16:00
Breakthrough Innovation in Cancer Care From Merck Pipeline to Be Presented at ASCO 2020 2020-05-14 06:46
Data From Merck at ASCO 2020 to Showcase Significant Clinical Advances in Cancer Care 2020-04-30 20:00
ERBITUX® Approved for First-line Use in China in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) 2020-03-02 15:02
European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma 2019-10-29 02:00
New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019 2019-09-27 14:00
New Data at ESMO 2019 for Merck Highlight Focused Clinical Development and Commitment to Patient Care 2019-09-23 14:00
CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma 2019-09-20 20:34
Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations 2019-09-11 14:30
Updated Results for Investigational Therapy Tepotinib Presented at WCLC 2019 2019-09-09 20:00
Merck Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with METex14 Skipping Mutations 2019-06-04 02:16
1